The utility of CEUS of the liver Webinar
The EFSUMB Webinar event, 'The utility of CEUS of the liver', will take place on Wednesday 19 April at 17.00 CEST and is chaired by Caroline Ewertsen and hosted by Sintesi on behalf of EFSUMB. Please view the speakers and use the button below to register for this event.
View the Speakers below ...
SPEAKER: Tommaso Bartolotta
Hospital Policlinico P. Giaconne, Palermo, Italy
Assessment of focal liver lesions with CEUS in comparison to CT/MRI
LEARNING OBJECTIVES:
1. To understand the main differences of microbubble-based contrast agent and extracellular contrast agents used in CT/MRI
2. To learn the role of CEUS in “non-oncologic non-cirrhotic patients”, “oncologic patients” and “cirrhotic patients” respectively
3. To be aware of the strength and the drawbacks of CEUS in the assessment of focal liver lesions in comparison to CT/MRI
SPEAKER: Annemaria Deganello
King's College Hospital, London, UK
CEUS as a problem-solving tool in the management of patients with focal liver lesions
LEARNING OBJECTIVES:
Coming Soon
SPEAKER: Franca Meloni
Casa di Cura Igea, Milan, Italy
CEUS for planning, guidance and monitoring of liver interventions
LEARNING OBJECTIVES:
CEUS plays a relevant role in the management of patients sent to ablation therapies in:
1. Pre-treatment planning
2. Intra-procedural and peri-procedural assessment
3. Follow-up
Abstract
• Ultrasound (US) is considered the first imaging modality used to guide percutaneous interventional procedures. CECT and CEMRI are frequently used to assess completeness of ablation.
• CEUS is an ideal imaging modality for the management of oncologic patients for clinical diagnostic imaging and interventional work-up during the planning, guidance, and immediate assessment of the treatment and follow-up.
• Planning of the treatment includes the assessment of size, number, vascularization and tumor margins of the ablation target.
• In pretreatment study, CEUS is complementary to CECT and/or CEMRI for tumor staging.
• During the procedure, CEUS can guide the needle insertion in cases of inconspicuity of the target or an occult tumor at unenhanced ultrasound.
• At the end of the ablation, multiple artifacts of post-procedure gas are present and require a 10/15 minute wait time for their resolution. When only a few bubbles of gas remain visible, CEUS reinjection permits detection of vascular residual tumor and guidance for immediate retreatment. This approach reduces incomplete ablation from 16 to 6% of cases.
• In the assessment of tumor post ablation, the use of CEUS is indicated when CECT or CEMRI are contraindicated or inconclusive. CEUS allows further information on the evaluation of tumor recurrence in both HCC and metastases and should be included in addition to CECT/CEMRI in follow-up protocols.